The McNair Group
McNair Group, based in Houston, Texas, is an investment advisory firm established in 1998, specializing in the energy and real estate sectors. The firm focuses on venture capital investments in technology startups within these industries. In addition to its investment activities, McNair Group offers a range of training and consultative services aimed at enhancing organizational culture and development. The firm is managed by an experienced executive team dedicated to delivering outcomes-based skills through professional coaching and support.
Xeris Biopharma is a specialty pharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. Utilizing its proprietary XeriSol and XeriJect technology platforms, the company delivers highly concentrated, liquid-stable formulations of peptides, small molecules, and proteins through various delivery methods, including syringes and auto-injectors. Xeris Biopharma's lead product is Gvoke, a ready-to-use glucagon for treating severe hypoglycemia, while its other products include Keveyis, the first FDA-approved treatment for primary periodic paralysis, and Recorlev, approved for endogenous hypercortisolemia in Cushing's Syndrome. The company is also advancing several product candidates in clinical trials, targeting conditions in endocrinology, neurology, and gastroenterology. Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma aims to improve patient care by providing easier-to-use therapies that enhance treatment outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.